Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Warm antibody hemolytic anemia


Other Names for this Disease
  • Warm antibody AIHA
  • Warm antibody autoimmune hemolytic anemia
  • Warm-reacting-antibody hemolytic anemia
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Overview


Warm antibody hemolytic anemia is the most common form of autoimmune hemolytic anemia. It is defined by the presence of  autoantibodies that attach to and destroy red blood cells at temperatures equal to or greater than normal body temperature.[1][2] The disease is characterized by symptoms related to anemia, including fatigue, difficulty breathing, jaundice and dark urine. In severe disease, fever, chest pain, syncope or heart failure may occur. Hemolysis (the breakdown of red blood cells) occurs mainly in the spleen, so mild splenomegaly is relatively common. Treatment typically involves a corticosteroid like prednisone. In cases that don't respond to treatment, splenectomy may be considered. Chronic and severe disease may be treated with Rituximab or immunosuppressive medications. [2] 
Last updated: 12/19/2012

References

  1. Lichtin AE. Autoimmune Hemolytic Anemia. Merck Manual. June 2008; http://www.merckmanuals.com/home/blood_disorders/anemia/autoimmune_hemolytic_anemia.html. Accessed 12/19/2012.
  2. Michel M. Autoimmune hemolytic anemia, warm type. Orphanet. August 2012; http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=90033. Accessed 12/19/2012.
Your Questions Answered
by the Genetic and Rare Diseases Information Center

Please contact us with your questions about Warm antibody hemolytic anemia. We will answer your question and update these pages with new resources and information.

Basic Information

In Depth Information

  • Orphanet is a European reference portal for information on rare diseases and orphan drugs.  Access to this database is free of charge.